Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: A case report

Case Reports in Oncology

Volumn 5, Issue 1, 2012, Pages 114-118

  Manjunath, Sadananda Rao ^a   Ramanan, Ganapathi ^b   Dedeepiya, Vidyasagar Devaprasad ^a   Terunuma, Hiroshi ^d   Deng, Xuewen ^d   Baskar, Subramani ^a   Senthilkumar, Rajappa ^a   Thamaraikannan, Paramasivam ^a   Srinivasan, Thangavelu ^a   Preethy, Senthilkumar ^a,c   Abraham, Samuel J K ^a,e  

^a C 16 and 17 Vijaya Health Centre Premises   (India)

^b Cancer Research and Relief Trust   (India)

^c Hope Foundation (Trust)   (India)

^d Biotherapy Institute of Japan   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Activated T lymphocytes (CD3+CD56+); Autologous immune enhancement therapy; Natural killer cells (CD3 CD56+); Recurrent ovarian carcinoma

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; AORTA DISSECTION; APPENDECTOMY; ARTICLE; ASCITES; BIOPSY; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CELL EXPANSION; CELL TRANSPLANTATION; CYSTADENOCARCINOMA; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HYSTERECTOMY; IMMUNITY; IMMUNOSTIMULATION; LAPAROTOMY; LIVER METASTASIS; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OMENTECTOMY; OVARY CARCINOMA; OVARY METASTASIS; PELVIS LYMPH NODE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SPLEEN METASTASIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84860714118     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000337319     Document Type: Article

References (10)

1. Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004;10:7439-7449.
2. Modugno F, Ovarian Cancer and High-Risk Women Symposium Presenters: Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003;91:15-31.
3. Lake RA, Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005;5:397-405.
4. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-807.
5. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002;8:1767-1771.
6. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K: Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995;1:501-507.
7. Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 2011;18:64-67.
8. Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, Murugan P, Thamaraikannan P, Srinivasan T, Preethy S, Abraham SJK: A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncology Letters 2011;3:435-440.
9. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14:195-208.
10. El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T, Zheng D, Krainer M: Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther 2010;9:1007-1018.